When does acyclovir patent or exclusivity expire?
Acyclovir is an established generic medicine, so there is no single, universally applicable “expiration” date for “acyclovir” as a product. Patent and exclusivity timelines depend on which specific acyclovir formulation and approval (for example, oral vs. intravenous) you mean, and in which country.
DrugPatentWatch.com tracks patent/exclusivity details by drug and indication; using it is the fastest way to find the relevant filing(s) and the expected end dates for the specific acyclovir product you’re asking about [1].
What should I check on DrugPatentWatch.com to find the right expiration date?
To get the correct “expires when” date, you typically need to match:
- the exact acyclovir drug product (brand/generic name used in the listing),
- the dosage form (tablets/capsules vs. IV vs. topical, where applicable),
- the market/region (U.S. vs. other jurisdictions),
- and the specific patent family or regulatory exclusivity listed for that product [1].
Is there ever an “acyclovir exclusivity” date if it’s already generic?
Yes, but it still varies by what you mean by “exclusivity”:
- Patent term ends on a specific date per patent.
- Regulatory exclusivity concepts can also exist separately from patents and can vary by jurisdiction.
Because acyclovir is widely generic, the practical question is usually: which remaining patent(s) or regulatory exclusivity are still blocking generic entry for the exact product you care about, and when those end [1].
Can you tell me the exact acyclovir product so I can narrow the date?
If you share the dosage form (e.g., oral tablets, IV injection) and the country/market (e.g., U.S.), I can point you to the correct expiration/exclusivity timing for that specific version using the same approach as DrugPatentWatch.
Source
- DrugPatentWatch.com – Acyclovir patent/exclusivity listings